Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR30206 in Patients With Advanced or Metastatic Solid Tumors
NCT06132828Phase 1Recruiting
- Sponsor
- Doer Bio
- Start
- Nov 2023
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of DR30206 in solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Doer Bio. Primary endpoints: Incidence of dose limiting toxicities at 21 days, Maximum tolerated dose at 21 days and 5 more. Started Nov 2023; status: recruiting.
02
Drugs
DR30206
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06132828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132828.